Written question asked by Lord Mendelsohn (Labour) on Thursday, 19 January 2023, in the House of Lords. It was due for an answer on Thursday, 2 February 2023. It was answered by Lord Markham (Conservative) on Thursday, 2 February 2023 on behalf of the Department of Health and Social Care.
Coronavirus: Immunosuppression
- Question
-
To ask His Majesty's Government what data the COVID-19 Therapeutics Clinical Review Panel are currently reviewing to inform its advice to Government in relation to support for at-risk patient cohorts.
- Answer
-
The Therapeutics Clinical Review Panel (TCRP) periodically reviews new evidence on the definition and revision of eligible cohorts from COVID-19 therapeutics from several sources, including clinical evidence, expert groups and external stakeholders. The Panel will meet again soon to consider more recent evidence on COVID-19 risk, including the National Institute for Health and Care Research rapid study on those who remain vulnerable to poor outcomes from COVID-19 despite vaccination.
Following the next meeting, any new recommendations will be published on the TCRP webpage, including a list of the evidence that has been reviewed.
Secondary information
- Type
- Written question
- Reference
- HL4910
- Session
- 2022-23
- Related items
- Subjects
- Coronavirus Immunosuppression
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-03-30 13:59:16 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL4910
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL4910
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL4910